




RealRate

PHARMACEUTICAL 2014

International Stem Cell CORP
Rank 195 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of International Stem Cell CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 10% points. The greatest weakness of International Stem Cell CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is 126%, being 117% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	4,626
Cost of Goods Sold	1,643
Intangible Assets	2,250
Liabilities, Current	7,021
Liabilities, Non-Current	0
Other Assets	33
Other Compr. Net Income	0
Other Expenses	2,457
Other Liabilities	0
Other Net Income	-2,933
Other Revenues	6,147
Property and Equipment	830
Research and Development	3,560
Selling, General and Administrative Expense	6,033

Output Variable	Value in 1000 USD
Assets	7,739
Liabilities	7,021
Expenses	13,693
Revenues	6,147
Stockholders Equity	718
Net Income	-10,479
Comprehensive Net Income	-10,479
BaseVar	18,766
ECR before Limited Liability	-121%
Economic Capital Ratio	126%